Methods for treating early morning pathologies
First Claim
1. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment, a time-specific controlled release dosage formulation comprising consisting essentially of (1) a core including at least one pharmaceutically active agent effective for the treatment of said morning pathology, and (2) a an outer swellable and erodible polymeric coating layer substantially surrounding said core;
- wherein said formulation is administered prior to sleep, and wherein said swellable polymeric coating layer delays the release of said pharmaceutically active agent from said core for a predetermined period of time dependent upon the thickness of said swellable polymeric coating layer, to permit delivery of said pharmaceutically active agent at about the time of awakening and to treat said early morning pathology.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the treatment of the specific early morning pathology to be treated, at about the time of awakening. The time-specific controlled release dosage formulation comprises (1) a core including the pharmaceutically active agent(s) effective for the treatment of the early morning pathology, and (2) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer, to effect delivery of the pharmaceutically active agent at about the time of awakening.
-
Citations
31 Claims
-
1. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment, a time-specific controlled release dosage formulation comprising consisting essentially of (1) a core including at least one pharmaceutically active agent effective for the treatment of said morning pathology, and (2) a an outer swellable and erodible polymeric coating layer substantially surrounding said core;
- wherein said formulation is administered prior to sleep, and wherein said swellable polymeric coating layer delays the release of said pharmaceutically active agent from said core for a predetermined period of time dependent upon the thickness of said swellable polymeric coating layer, to permit delivery of said pharmaceutically active agent at about the time of awakening and to treat said early morning pathology.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
28. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment a time-specific controlled release dosage formulation comprising:
-
(1) a core including at least one pharmaceutically active agent effective for the treatment of said morning pathology, and (2) an outer swellable polymeric coating layer substantially surrounding said core;
wherein said formulation is administered prior to sleep, and wherein swelling and erosion of said swellable polymeric coating layer inhibits the release of said pharmaceutically active agent from said core for a predetermined period of time dependent solely upon the thickness of said swellable polymeric coating layer, to permit delivery of said pharmaceutically active agent at about the time of awakening and to treat said early morning pathology.
-
-
29. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment, a time-specific controlled release dosage formulation comprising:
-
(1) a core including at least one pharmaceutically active agent effective for the treatment of said morning pathology, and (2) an outer, erodible, swellable polymeric coating layer consisting essentially of at least one swellable polymer substantially surrounding said core;
wherein said formulation is administered prior to sleep, and wherein the time delay before release of said pharmaceutically active agent from said core is solely dependent on the thickness of said swellable polymer, to permit delivery of said pharmaceutically active agent at about the time of awakening and to treat said early morning pathology.
-
-
30. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment a time-specific controlled release dosage formulation comprising:
-
(1) a core including at least one pharmaceutically active agent effective for the treatment of said morning pathology, and (2) an outer, erodible swellable polymeric coating layer consisting essentially of at least one swellable polymer substantially surrounding said core;
wherein said formulation is administered prior to sleep, and wherein said swellable polymeric coating layer controls the time delay before release of said pharmaceutically active agent from said core for a predetermined period of time dependent upon the thickness of said swellable polymeric coating layer, to permit delivery of said pharmaceutically active agent at about the time of awakening and to treat said early morning pathology.
-
-
31. A method for treating an early morning pathology, said method comprising administering to a subject in need of treatment a time-specific controlled release dosage formulation consisting essentially of:
-
a first time-specific dosage unit consisting essentially of;
(1) a first core including a pharmaceutically active agent effective for the treatment of said morning pathology and a disintegration enhancing agent, and (2) a first, outer swellable and erodible polymeric coating layer substantially surrounding said core;
wherein the thickness of said first swellable polymeric coating layer controls the release of said pharmaceutically active agent from said first core for a predetermined period of time dependent upon the thickness of said first swellable polymeric coating layer; and
a second time-specific dosage unit consisting essentially of;
(1) a second core including the pharmaceutically active agent effective for the treatment of said morning pathology, and (2) a second swellable and erodible polymeric coating layer substantially surrounding said core;
wherein the thickness of said second swellable polymeric coating layer controls the release of said pharmaceutically active agent from said second core for a predetermined period of time dependent upon the thickness of said second swellable polymeric coating layer,wherein said formulation is administered to the subject prior to sleep, to permit delivery of said pharmaceutically active agent at about the time of awakening, and to treat said early morning pathology.
-
Specification